Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE02 Dose-response Study in Healthy Subjects
NCT05979727Phase 1Terminated
- Sponsor
- Reconnect Labs
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mebufotenin in generalized anxiety disorder (GAD) (4 arms), sponsored by Reconnect Labs. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 6 more. Started Nov 2023; status: terminated.
02
Drugs
mebufotenin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT05979727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979727.